An FDA advisory committee recommended expanding compounding access for unapproved peptides BPC-157 and KPV, following narrow votes that occurred amid policy controversy over evidence and patient-safety standards. FDA panelists supported lifting restrictions on compounded manufacturing, while the underlying data set cited by critics was characterized as lacking substantive evidence on benefits and safety. The recommendations are non-binding, and the FDA is expected to decide whether to adjust restrictions that have limited access to these peptides. The votes cover additional peptides as well, with later decisions on other substances scheduled as the agency weighs whether to expand the Section 503A Bulk Drug Substances List. The decision pathway matters for drug supply economics and patient access, particularly for compounding pharmacies operating outside the usual branded and generic approval framework.